San-Qi Zhang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7829911/publications.pdf

Version: 2024-02-01

		430874	501196
47	935	18	28
papers	citations	h-index	g-index

47	47	47	885
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Small molecule selenium-containing compounds: Recent development and therapeutic applications. European Journal of Medicinal Chemistry, 2021, 223, 113621.	5.5	108
2	Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC). European Journal of Medicinal Chemistry, 2020, 189, 112061.	5.5	82
3	Discovery of potent small molecule PROTACs targeting mutant EGFR. European Journal of Medicinal Chemistry, 2020, 208, 112781.	5.5	58
4	Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors. European Journal of Medicinal Chemistry, 2020, 186, 111888.	5.5	43
5	Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity. Bioorganic and Medicinal Chemistry, 2015, 23, 6477-6485.	3.0	39
6	Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs. European Journal of Medicinal Chemistry, 2018, 148, 221-237.	5.5	36
7	Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere. European Journal of Medicinal Chemistry, 2014, 75, 96-105.	5.5	34
8	Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2015, 96, 382-395.	5.5	33
9	Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands. Journal of Medicinal Chemistry, 2022, 65, 4709-4726.	6.4	32
10	Combination of 2-methoxy-3-phenylsulfonylaminobenzamide and 2-aminobenzothiazole to discover novel anticancer agents. Bioorganic and Medicinal Chemistry, 2014, 22, 3739-3748.	3.0	26
11	Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 2173-2185.	3.0	26
12	Synthesis and antitumor activity evaluation of 4,6-disubstituted quinazoline derivatives as novel PI3K inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4408-4413.	2.2	24
13	Synthesis of Aryl Trimethylstannane via BF₃Â·OEt₂-Mediated Cross-Coupling of Hexaalkyl Distannane Reagent with Aryl Triazene at Room Temperature. Journal of Organic Chemistry, 2019, 84, 463-471.	3.2	23
14	Discovery of 4-benzoylamino-N-(prop-2-yn-1-yl)benzamides as novel microRNA-21 inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 6510-6519.	3.0	21
15	Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3KÎ´ inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1972-1977.	2.2	21
16	Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3KÎ´) inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 2028-2040.	3.0	21
17	Novel PI3K/Akt/mTOR signaling inhibitor, W922, prevents colorectal cancer growth via the regulation of autophagy. International Journal of Oncology, 2020, 58, 70-82.	3.3	20
18	Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety. Bioorganic and Medicinal Chemistry, 2015, 23, 7765-7776.	3.0	19

#	Article	IF	Citations
19	Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents. Bioorganic and Medicinal Chemistry, 2016, 24, 179-190.	3.0	19
20	Discovery of 2-aryl-8-hydroxy (or methoxy)-isoquinolin-1(2H)-ones as novel EGFR inhibitor by scaffold hopping. Bioorganic and Medicinal Chemistry, 2013, 21, 6956-6964.	3.0	16
21	Synthesis and cytotoxic activity of diaryl urea derivatives with a 4-methylpiperazinylcarbonyl moiety. Medicinal Chemistry Research, 2013, 22, 3857-3862.	2.4	15
22	F10, a new camptothecin derivative, was identified as a new orallyâ€“bioavailable, potent antitumor agent. European Journal of Medicinal Chemistry, 2020, 202, 112528.	5.5	15
23	Design, synthesis and antiproliferative activity evaluation of m -(4-morpholinyl-1,3,5-triazin-2-yl)benzamides in vitro. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1730-1735.	2.2	14
24	Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold. Bioorganic and Medicinal Chemistry, 2018, 26, 3619-3633.	3.0	14
25	Synthesis and antitumor activity evaluation of 2-arylisoquinoline-1,3(2H,4H)-diones in vitro and in vivo. Medicinal Chemistry Research, 2014, 23, 1340-1349.	2.4	13
26	Discovery of novel 3-benzylquinazolin-4(3 H)-ones as potent vasodilative agents. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5597-5601.	2.2	13
27	Modification of N -(6-(2-methoxy-3-(4-fluorophenylsulfonamido)pyridin-5-yl)-[1,2,4]triazolo[1,5- a) Tj ETQq1 1 0.784314 rgBT /Overlock Bioorganic and Medicinal Chemistry, 2015, 23, 5662-5671.	3.0	12
28	Metal-Free C-2-H Alkylation of Quinazolin-4-ones with Alkanes via Cross-Dehydrogenative Coupling. Organic Letters, 2019, 21, 2365-2368.	4.6	12
29	Discovery of 2-(pyridin-2-yl)aniline as a directing group for the sp² Câ€“H bond amination mediated by cupric acetate. Organic and Biomolecular Chemistry, 2017, 15, 6622-6631.	2.8	11
30	Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors. Bioorganic and Medicinal Chemistry, 2019, 27, 114930.	3.0	11
31	Recent Progress of Small Molecule Meninâ€“MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia. Journal of Medicinal Chemistry, 2021, 64, 15519-15533.	6.4	11
32	Menin-MLL protein-protein interaction inhibitors: a patent review (2014â€“2021). Expert Opinion on Therapeutic Patents, 2022, 32, 507-522.	5.0	11
33	Cu-mediated selective bromination of aniline derivatives and preliminary mechanism study. Synthetic Communications, 2019, 49, 1406-1415.	2.1	10
34	Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3KÎ´ inhibitors. Bioorganic and Medicinal Chemistry, 2019, 27, 115035.	3.0	9
35	Research advances on selective phosphatidylinositol 3 kinase Î´ (PI3KÎ´) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127457.	2.2	9
36	Synthesis and Biological Evaluation of 10â€Substituted Camptothecin Derivatives with Improved Water Solubility and Activity. ChemMedChem, 2021, 16, 1000-1010.	3.2	9

#	Article	IF	Citations
37	Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3KÎ´) inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 651-656.	5.2	7
38	Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor. Future Medicinal Chemistry, 2018, 10, 2445-2455.	2.3	7
39	The dual luciferase reporter system and RTâ€qPCR strategies for screening of MicroRNAâ€21 smallâ€molecule inhibitors. Biotechnology and Applied Biochemistry, 2019, 66, 755-762.	3.1	6
40	K₂S₂O₈-promoted Câ€“Se bond formation to construct Î±-phenylseleno carbonyl compounds and Î±,Î²-unsaturated carbonyl compounds. RSC Advances, 2020, 10, 28902-28905.	3.6	6
41	Discovery of novel 2-benzylisoquinolin-1(2H)-ones as potent vasodilative agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5808-5812.	2.2	4
42	Vasodilation and hypotension of a novel 3-benzylquinazolin- 4(3H)-one derivative via the inhibition of calcium flux. European Journal of Pharmacology, 2016, 791, 741-750.	3.5	4
43	Copper-Mediated monochlorination of anilines and nitrogen-containing heterocycles. Synthetic Communications, 2018, 48, 2708-2714.	2.1	4
44	Triazene as the Directing Group Achieving Highly Ortho-Selective Diborylation and Sequential Functionalization. Organic Letters, 2022, , .	4.6	4
45	W941, a new PI3K inhibitor, exhibits preferable anti-proliferative activities against nonsmall cell lung cancer with autophagy inhibitors. Investigational New Drugs, 2020, 38, 1218-1226.	2.6	3
46	Irreversible epidermal growth factor receptor inhibitor Z25h exhibits pronounced inhibition on non-small cell lung adenocarcinoma cell line Hcc827. Anti-Cancer Drugs, 2021, 32, 417-426.	1.4	0
47	Identification of benzamides derivatives of norfloxacin as promising microRNA-21 inhibitors via repressing its transcription. Bioorganic and Medicinal Chemistry, 2022, 66, 116803.	3.0	0